Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.485 USD | -3.13% | +8.33% | -81.95% |
05-14 | Wolfe Research Downgrades RAPT Therapeutics to Peer Perform From Outperform | MT |
05-10 | Guggenheim Downgrades RAPT Therapeutics to Neutral From Buy | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-81.95% | 157M | |
+10.79% | 116B | |
+11.65% | 106B | |
-6.20% | 23.89B | |
-2.33% | 21.58B | |
-6.03% | 18.96B | |
-13.41% | 16.33B | |
-40.50% | 16.96B | |
+6.64% | 14.14B | |
+31.84% | 12.02B |
- Stock Market
- Equities
- RAPT Stock
- News RAPT Therapeutics, Inc.
- Stifel Initiates Coverage on RAPT Therapeutics with Buy Rating, $40 Price Target